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A commentary on
Production and characterization ofmonoclonal antibodies to human interleukin 2: strategy and
tactics
by Smith KA, Favata MF, Oroszlan S. J Immunol (1983) 131:1808–15.
Although we had successfully created antigen-specific cytolytic T lymphocyte lines (CTLLs) using
conditioned media as a source of growth-promoting factors, we had no effective method to
determine the relative activities of different batches of conditioned media. Therefore, it was crucial
to create a quantitative assay for the activity we termed “T cell growth factor” (TCGF). Fortunately,
Torgny Fredrickson and I had already created a bioassay for the red blood cell growth factor,
erythropoietin (EPO), usingmurine fetal liver cells that are enriched for EPO-responsive precursors
(1, 2). Thus, patterned on the EPO bioassay, it was straightforward to construct a similar assay for
TCGF using as target cells our long-term CTLL. The critical elements of the assay were (1) a low
density of CTLL target cells and (2) serial twofold dilutions of conditioned media samples, thereby
establishing a dose–response curve that allowed comparison of separate conditioned media (3). Of
note was the observation that the curve was symmetrically sigmoid when the linear responses of
tritiated thymidine incorporation were plotted vs. the logarithm of the conditioned media dilutions.
We arbitrarily assigned 1.0U/mL that yielded 50% of maximal growth promotion at a dilution of
1:10. This assay represented the first ever quantitative bioassay for a lymphokine.
Thus, armed with a rapid, quantitative bioassay, we next sought to generate T cell clones derived
from our antigen-specific CTLL so that we could assess the potential problem of target cell hetero-
geneity. We tried two established cloning methods: (1) dilute cell suspensions seeded into soft agar
containing TCGF-conditioned media and (2) limiting dilution (0.03–0.01 cells/well) in microtiter
plates containing TCGF-conditioned media. The limiting dilution technique in suspension culture
worked very well, yielding 67–100% plating efficiency. This was the first description of monoclonal
antigen-specific cytolytic T cells (4). Accordingly, T cell clones permitted an unambiguous interpre-
tation that TCGFwas acting directly on clonedT cells and not indirectly through an intermediate cell
type, e.g., an APC. We submitted our manuscript to Nature, which again rejected it without review
[see Ref. (5)], so that we immediately reformatted it and sent it to the J. Exp. Med., which accepted
it without changes, so much for non-scientist journalists (Nature) vs. peer scientists (JEM) making
informed editorial decisions (6). Other investigators rapidly adopted these cloning methods, in that
they not only allowed for separation of the cell clones, but also could be used to grow large numbers
of progeny, which could be used for both biological and molecular characterizations. The ability to
createmonoclonal functional T cells was as transformative for T cells asmonoclonal antibodies were
for B cells.
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The foregoing results of these studies on the various mito-
genic activities in conditioned media pointed to the over-
whelming need to identify the molecules responsible for the
bioactivities. In addition, the molecular mechanisms whereby the
mitogenic activities interacted with their target cells loomed as
a huge overriding question. Thus, armed with the quantitative
TCGF bioassay, analytical biochemical experimental approaches
yielded results consistent with a single, small protein (~15.5 kDa;
pI= 8.2) as solely promoting the biological response (7). This
was an important finding, in that it meant that further purifi-
cation of the molecule responsible for the activity would be
straightforward, whereas if several molecules cooperated to pro-
duce the activity, purification of each component would be
difficult.
These biochemical approaches permitted the separation and
purification of enough biosynthetically radiolabeled TCGF to
permit classic hormone binding assays, which revealed that radi-
olabeled TCGF-binding sites expressed all of the characteristics
of true hormone receptors, i.e., the binding was restricted to
TCGF-responsive cells, there was a lack of competition by other
growth factors and hormones, the binding was of very high
affinity, and there was a close correlation between the TCGF
concentrations that bound to cells and those that mediated the
proliferative response (8). These data all supported the conclusion
that the binding site detected was on the receptor through which
the biological effects of TCGF are initiated. This report was the
first to demonstrate and characterize a cytokine receptor, and
consequentially became the prototype for the identification and
characterization of all subsequent cytokine receptors involved in
regulating immune and inflammatory responses. Moreover, the
radiolabeled TCGF binding assay was absolutely instrumental in
the identification of the first monoclonal antibody reactive with a
cytokine receptor molecule (9).
These experimental approaches allowed us to calculate
the Specific Activity of IL-2 for the first time, so that
1.0U/mL= 150 ng/mL, which indicated that we would need to
start with several liters of conditioned media to concentrate and
purify adequate IL-2 protein to immunize mice with microgram
amounts of TCGF protein and ultimately to develop the first
monoclonal antibodies reactive with a lymphokine molecule
(10). Prior to the development of quantitative bioassays and
radioreceptor assays, investigators had tested only one dilution
of a sample, e.g., a 1:2 or a 1:4, so that they could not quantify
the amount of activity and relate it to a measured protein
concentration. Thus, attempts were made to purify cytokine
molecules with only 10–100mL of starting conditioned media.
In this article, we detailed the critical experimental approaches
and advances that led to our success in generating monoclonal
antibodies reactive with human TCGF, so that others might
follow. Through rigorous biochemical analytic methods, it was
possible to prove that the monoclonal antibodies were useful
to immunoaffinity purify IL-2 molecules to homogeneity in
milligram quantities from multiple liters of conditioned media
that then could be used for unambiguousmolecular and biological
characteristics of the first interleukin molecule to be identified.
Thus, with these new and novel cellular andmolecular reagents,
we could proceed to experiments that had never been done before.
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